Actualizaciones regulatorias

Policy director Jeon Jin‑han cautions that the government's plan to broaden medication delivery for telemedicine patients could increase private platform control and push medical privatization.

Over three decades, the KPA has formed emergency committees for major policy issues, noting varied outcomes influenced by political, social and public factors.

Pharmacists and civil groups in South Korea are staging protests and a nationwide rally after a petition against remote prescription drug delivery gathered 50,000 signatures.

The PMDA-ATC workshop in Tokyo (Jan 26‑29, 2027) offers free training on MRCT review and GCP inspection for APEC regulatory officials.

Pharmacists rallied outside the Blue House, demanding a halt to the government's plan to broaden telemedicine and prescription drug delivery, urging stronger primary care and public health infrastructure.

The Korean Ministry of Food and Drug Safety inspected the pilot K‑NASS system, aiming to detect misuse and illegal distribution of medical narcotics more rapidly.

On June 13, pharmacists and allied health groups gathered in front of Seoul’s Blue House to protest the government's plan to broaden telemedicine‑based prescription drug delivery, urging a policy review.

KDCA announced a 2026‑2027 influenza epidemic warning on Sep 11, citing rapid rise in cases among school‑age children and infants and urging preventive measures in group settings.

The Korean Pharmaceutical Association calls for dropping in‑hospital compounding of abortion induction drugs and pushing for health‑insurance reimbursement, warning against utilization barriers.

A relay protest in front of Seoul’s Blue House entered its 359th day, with officials urging the government and parliament to clarify and reform the licensing system for pharmacists and herbal pharmacists.

The US FDA has expanded the indication of Bayer’s oral TKI Hyrnuo, granting accelerated approval as first‑line therapy for HER2‑mutated locally advanced or metastatic non‑squamous NSCLC, based on a 75% ORR in the SOHO‑01 trial.

Alvogen’s discontinued topical gel CICLOPIROX (0.77%) received FDA labeling submissions in 2013, with earlier filings dating back to 1997.